奥翔药业(603229) - 2020 Q3 - 季度财报

Financial Performance - Operating income for the first nine months was ¥301,869,865.51, representing a growth of 48.39% year-on-year[18]. - Net profit attributable to shareholders for the first nine months was ¥66,188,985.18, up 31.64% from the same period last year[18]. - The net cash flow from operating activities for the first nine months was ¥91,166,092.40, an increase of 21.42% year-on-year[18]. - Basic earnings per share for the reporting period was ¥0.30, reflecting a growth of 36.36% compared to ¥0.22 in the previous year[21]. - The weighted average return on net assets increased to 9.84%, up 1.71 percentage points from 8.13%[21]. - The net profit after deducting non-recurring gains and losses for the first nine months was ¥62,828,848.44, a year-on-year increase of 41.80%[18]. - Total operating revenue for Q3 2020 reached ¥91,996,528.64, a 24.2% increase from ¥74,178,844.61 in Q3 2019[51]. - Net profit for Q3 2020 was ¥13,590,978.49, a decrease of 29.3% compared to ¥19,241,930.33 in Q3 2019[56]. - Total comprehensive income for the first three quarters of 2020 was ¥63,693,772.80, compared to ¥50,235,480.06 in the same period of 2019, an increase of 26.8%[63]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥912,947,302.64, an increase of 3.02% compared to the end of the previous year[18]. - Total liabilities decreased to CNY 214,007,088.45 from CNY 240,959,423.97, a decline of about 11.2%[43]. - The company's equity increased to CNY 698,940,214.19 from CNY 645,185,357.03, reflecting a growth of about 8.35%[43]. - Current assets totaled CNY 590,765,168.30, slightly down from CNY 601,626,765.83 year-over-year[41]. - Total liabilities as of the reporting date were ¥214,173,102.30, compared to ¥241,175,353.69 in the previous period[51]. - Total equity increased to ¥697,141,533.59 from ¥645,447,760.79 in the previous period[51]. Cash Flow - Cash generated from operating activities for the first three quarters of 2020 was ¥327,572,274.86, up from ¥231,786,482.82 in the same period of 2019, representing a 41.3% increase[64]. - Operating cash inflows totaled CNY 387,240,896.23, an increase from CNY 270,115,109.82 in the previous period, representing a growth of approximately 43.4%[67]. - Operating cash outflows amounted to CNY 296,074,803.83, compared to CNY 195,030,913.70 in the prior period, reflecting an increase of about 52.0%[67]. - The net increase in cash and cash equivalents was CNY -11,924,036.80, compared to CNY -7,833,410.64 in the previous period[69]. - The ending balance of cash and cash equivalents was CNY 305,702,785.14, up from CNY 259,131,999.40[69]. Expenses - Research and development expenses increased by 46.71% to RMB 42,818,195.53, up from RMB 29,185,849.94 in the same period last year, indicating a focus on innovation[30]. - The company reported a 37.07% increase in operating costs, totaling RMB 132,095,051.78, compared to RMB 96,368,480.34 in the previous year, driven by increased sales[30]. - The company’s management expenses rose by 43.66% to RMB 44,013,415.41, up from RMB 30,636,337.17, indicating higher operational costs[30]. - The company’s financial expenses increased by 130.27%, resulting in RMB 3,359,431.63 due to foreign exchange losses[30]. - Financial expenses for Q3 2020 were ¥10,459,021.55, compared to a gain of ¥7,212,342.85 in Q3 2019, indicating a significant shift in financial performance[59]. Shareholder Information - The total number of shareholders at the end of the reporting period was 12,944[24]. - The largest shareholder, Zheng Zhiguo, held 59.99% of the shares, totaling 134,366,400 shares[24]. Investment Activities - The company's cash flow from investing activities showed a net outflow of RMB -68,356,496.74, a 79.97% increase in outflow compared to RMB -37,982,171.76 in the previous year, primarily due to land purchases[33]. - Investment cash outflows reached CNY 158,001,316.73, a decrease from CNY 174,620,152.06, showing a reduction of about 9.5%[67]. Other Information - The company has not reported any new products or technologies in this quarter[86]. - There are no updates on market expansion or mergers and acquisitions in the current report[86].